Personalized Therapies and Clinical Outcomes for Older Patients with Lymphoma
A special issue of Hematology Reports (ISSN 2038-8330).
Deadline for manuscript submissions: 31 December 2024 | Viewed by 1886
Special Issue Editor
Interests: older adults; diffuse large B-cell lymphoma; clinical trial; new drugs; comorbidity; dose intensity; comprehensive geriatric assessment; quality of life
Special Issue Information
Dear Colleagues,
By 2025, people 65 years or older will comprise about 20 percent of the total population in Japan. Among older adults, the percentage of patients over 80 years old will increase in Western Europe, China, and Japan. Recently several new drugs have been developed for the treatment of diffuse large B-cell lymphoma (DLBCL), including DLBCL biology, tumor microenvironment and epigenetics, some new therapies and drugs like molecular and signal pathway target therapy, chimeric antigen receptor T-cell therapy, immune checkpoint inhibitors, antibody drug-conjugate and tafasitamab. In clinical trials, patients with a poor performance status or renal, hepatic, or bone marrow dysfunction generally have been excluded, thus raising questions about the general applicability of data derived from such trials. This is particularly true for patients over 80 years. This special issue aims to collect and publish original research articles and reviews demonstrating recent advance in our knowledge on new diagnostic and therapeutic approaches in these clinical conditions with regarding the personalization of the patient's treatment based on his clinical characteristics, comorbidities, and preference.
Dr. Satoshi Yamasaki
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Hematology Reports is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- older adults
- diffuse large B-cell lymphoma
- clinical trial
- new drugs
- comorbidity
- dose intensity
- comprehensive geriatric assessment
- quality of life
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
